In 2020, the Chinese market will become the performance booster of multinational pharmaceutical enterprises

[trends of pharmaceutical network industry] in 2019, major pharmaceutical enterprises, especially multinational enterprises, took frequent actions in the pharmaceutical market However, in fact, the benefits of multinational pharmaceutical enterprises in 2019 are not very obvious, and the effect of "slimming" measures such as M & A and divestiture to drive performance recovery remains to be seen On the whole, for the Chinese market, it will still be the main propeller of the future performance of these multinational enterprises It is understood that at present, many enterprises have successively disclosed the 2019 annual report It is worth noting that many of the multinational pharmaceutical companies mentioned the Chinese market Novartis, for example, announced its 2019 results on January 29 And first mentioned China's performance in the financial report According to the financial report, Novartis China's market volume has grown by double digits and is expected to double in 2024 In addition, in the past two years, Novartis has approved 24 new drug applications (NDA) for 9 new molecular entities in China In the next five years, it plans to submit another 50 new drug applications Therefore, Novartis may apply for more than 70 NDA in total Besides Novartis, China is also a very important market for other enterprises For example, in recent years, Geely Germany has frequently acted in the Chinese market It is understood that since 2017, Gilead has successively obtained 8 drugs approved by nmpa, and 4 new drugs have entered the national medical insurance catalog China's novel coronavirus pneumonia was also the focus of attention at the beginning of this year, and its children were also studied Reed and his group were included in the study If the drugs were validated, the Chinese market would bring huge orders to them Geely expects its hepatitis B drug, vemlidy, to generate $1 billion in revenue in 2022 as it penetrates the U.S market and drives the Chinese market In addition, from January 28, Pfizer announced its 2019 results, the Chinese market has also become a strong driving force for its performance According to its annual report, Pfizer has achieved a total revenue of $52.75 billion, down 1% year on year From the perspective of segment business, the total revenue of biopharmaceutical business for the whole year was US $39.4 billion, an increase of 8%; the revenue of general strength business reached US $10.233 billion, a decrease of 16% In contrast, its revenue in China rose by 7% In fact, as one of the early foreign pharmaceutical companies entering China, Pfizer has always been a supporter and beneficiary of China's innovation and openness Last year, Pfizer said it would continue to work in China to bring more innovative treatment options to patients and change their lives Looking back over the past year, the growth rate of multinational pharmaceutical enterprises has slowed down, and the news of layoffs and burden shedding continues Thanks to the favorable policies, the rising local pharmaceutical enterprises have also brought challenges to multinational pharmaceutical enterprises However, due to the large population base and the growing demand for drugs, China is still attractive to multinational pharmaceutical enterprises In the future, in the Chinese market where opportunities and challenges coexist, multinational pharmaceutical enterprises may open a new chapter, and the competition with local pharmaceutical enterprises may continue to intensify.